MeSH Browser

MeSH Heading: Transforming Growth Factor beta2
Tree Number(s): D12.644.276.374.687.200; D12.644.276.954.775.200; D12.776.467.374.687.200; D12.776.467.942.775.200; D23.529.374.687.200; D23.529.942.775.200
Unique ID: D053781
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D053781
Scope Note: A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
Entry Term(s): BSC-1 Cell Growth Inhibitor; Cartilage-Inducing Factor-B; Glioblastoma-Derived T-Cell Suppressor Factor; Polyergin; Suppressor Factor, T-Cell, Glioblastoma-Derived; TGF-beta-2; TGF-beta2; TGF-beta2 Latency-Associated Protein; TGF-beta2LAP; Transforming Growth Factor beta 2 Latency Associated Peptide
Public MeSH Note: 2007; TRANSFORMING GROWTH FACTOR BETA2 was indexed under TRANSFROMING GROWTH FACTOR BETA 2000-2006
History Note: 2007(2000)
Date Established: 2007/01/01
Date of Entry: 2006/07/05
Revision Date: 2015/06/02

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

deficiency (DF)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Concept UI: M0024759
Scope Note: A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
Terms: Transforming Growth Factor beta2 Preferred Term
Term UI T410587
Date03/29/2000
LexicalTag NON
ThesaurusID NLM (2007); BSC-1 Cell Growth Inhibitor
Term UI T048244
Date02/27/1990
LexicalTag ABX
ThesaurusID NLM (2007); Glioblastoma-Derived T-Cell Suppressor Factor
Term UI T048246
Date02/27/1990
LexicalTag NON
ThesaurusID NLM (2007); Suppressor Factor, T-Cell, Glioblastoma-Derived
Term UI T048247
Date02/27/1990
LexicalTag NON
ThesaurusID NLM (2007); Polyergin
Term UI T048249
Date02/27/1990
LexicalTag NON
ThesaurusID NLM (2007); TGF-beta2
Term UI T048250
Date02/27/1990
LexicalTag ABB
ThesaurusID NLM (2007); TGF-beta-2
Term UI T048251
Date01/16/1991
LexicalTag ABB
ThesaurusID NLM (2007); Cartilage-Inducing Factor-B
Term UI T175341
Date01/01/1955
LexicalTag NON
ThesaurusID NLM (2007)

Transforming Growth Factor beta2 MeSH Descriptor Data 2025